



Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain

Alba Grifoni,^a Michael Angelo,^a John Sidney,^a Sinu Paul,^a Bjoern Peters,^a Aruna D. de Silva,^{a,b} Elizabeth Phillips,^c Simon Mallal,^c Sean A. Diehl,^d Jason Botten,^d Jonathan Boyson,^d Beth D. Kirkpatrick,^d Stephen S. Whitehead,^e Anna P. Durbin,^f Alessandro Sette,^a Daniela Weiskopf^a

Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA^a; Genetech Research Institute, Colombo, Sri Lanka^b; Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia, and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA^c; University of Vermont College of Medicine and Vaccine Testing Center, Burlington, Vermont, USA^d; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA^e; Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA^f

ABSTRACT A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region (rDEN2Δ30) has previously been established for use in a controlled human DENV challenge model. To evaluate if this model is appropriate for the derivation of correlates of protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular immune response to this challenge strain to the response induced by natural infection. To achieve this, we predicted HLA class I- and class II-restricted peptides from rDEN2Δ30 and used them in a gamma interferon enzyme-linked immunosorbent spot assay to interrogate CD8⁺ and CD4⁺ T cell responses in healthy volunteers infected with rDEN2Δ30. At the level of CD8 responses, vigorous *ex vivo* responses were detected in approximately 80% of donors. These responses were similar in terms of the magnitude and the numbers of epitopes recognized to the responses previously observed in peripheral blood mononuclear cells from donors from regions where DENV is hyperendemic. The similarity extended to the immunodominance hierarchy of the DENV nonstructural proteins, with NS3, NS5, and NS1 being dominant in both donor cohorts. At the CD4 level, the responses to rDEN2Δ30 vaccination were less vigorous than those to natural DENV infection and were more focused on nonstructural proteins. The epitopes recognized following rDEN2Δ30 infection and natural infection were largely overlapping for both the CD8 (100%) and CD4 (85%) responses. Finally, rDEN2Δ30 induced stronger CD8 responses than other, more attenuated DENV isolates.

IMPORTANCE The lack of a known correlate of protection and the failure of a neutralizing antibody to correlate with protection against dengue virus have highlighted the need for a human DENV challenge model to better evaluate the candidate live attenuated dengue vaccines. In this study, we sought to characterize the immune profiles of rDEN2Δ30-infected subjects and to compare the profiles with those for subjects from areas where DENV is hyperendemic. Our data demonstrate that T cell responses to rDEN2Δ30 are largely similar to those to natural infection in terms of specificity, highlighting that the response to this virus in humans is appropriate as a model for the T cell response to primary DENV2 infection.

KEYWORDS T cells, dengue virus, human challenge model, vaccine

Received 27 October 2016 Accepted 28 January 2017

Accepted manuscript posted online 1 February 2017

Citation Grifoni A, Angelo M, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Botten J, Boyson J, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D. 2017. Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) support its suitability as a human dengue virus challenge strain. *J Virol* 91:e02133-16. <https://doi.org/10.1128/JVI.02133-16>.

Editor Adolfo García-Sastre, Icahn School of Medicine at Mount Sinai

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Daniela Weiskopf, daniela@lji.org.

The impact of dengue virus (DENV) on human health has dramatically increased in recent years. About 2.5 billion people are at risk of dengue virus transmission, and in more than 100 countries the infection is endemic (WHO and CDC). Primary (first-time) infection with one of the four DENV serotypes is often associated with a course of disease relatively less severe than that of secondary infections mediated by different serotypes. Indeed, the development of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) is most frequently associated with such heterologous secondary infections.

Accordingly, the development of a DENV vaccine that simultaneously induces immunity against all four DENV serotypes is of great importance. Several dengue vaccines are currently under clinical evaluation. Among them, Dengvaxia is a live attenuated tetravalent (LATV), chimeric, three-dose vaccine based on the expression of the pre-membrane (prM) and envelope (E) proteins of DENV serotype 1 (DENV1) to DENV4 within the backbone of the yellow fever virus 17D vaccine strain. Dengvaxia induced neutralizing antibodies against the four dengue virus serotypes, but recent trials have shown variable efficacy against symptomatic dengue and significantly lower efficacy in subjects who were immunologically naive to dengue virus prior to vaccination (1–3). Nonetheless, the Dengvaxia vaccine has been implemented on a restricted basis in some countries and populations. A vaccine that only partially protects from dengue virus infection may be of concern because of potential safety issues, increasing the risk of development of severe dengue disease in areas of endemicity, particularly where rates of transmission are low. In fact, there was a significantly higher risk of hospitalization due to subsequent dengue virus infection in only year 3 of the study for Dengvaxia recipients who were 2 to 5 years of age at the time of vaccination compared to the risk for controls (4).

While no firm correlate of protection against dengue virus has been defined (5), it is possible that optimal vaccination might require, in addition to antibody responses, CD4 and CD8 responses (6, 7). In this case, the use of the yellow fever virus backbone encoding the DENV E and prM antigens might be suboptimal, since DENV-specific CD4 and CD8 responses dominantly target the DENV capsid (C) and nonstructural (NS) proteins, respectively (8), which are not contained in the Dengvaxia vaccine. The DENV C and NS proteins are, however, encoded by tetravalent DENV live attenuated vaccine (TDLAV) constructs.

TDLAV candidates currently in development include the TV003 and the Takeda dengue-dengue chimera (TDV) vaccines (9). The TV003 vaccine is composed of four live attenuated recombinant dengue viruses (a deletion variant of the DENV2 Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region [rDEN1Δ30], rDEN2/4Δ30, rDEN3Δ30/31, and rDEN4Δ30) and is being developed by the Laboratory of Infectious Diseases at the National Institutes of Health (NIH). The TV003 vaccine has been shown to have acceptable safety, infectivity, and immunogenicity profiles, making it a very promising vaccine candidate (6, 10–12).

A controlled human dengue virus challenge model would more directly allow correlates of protection from DENV infection and disease to be established and would facilitate the evaluation and development of novel vaccine candidates. Previous data have shown that the DENV2 component has the lowest efficacy following Dengvaxia vaccination and also induces the lowest frequency of seroconversion following TV003 vaccination, suggesting that a human challenge model for DENV2 would be of particular practical interest (4, 11).

rDEN2Δ30 derives from a DENV2 isolate identified in the 1974 outbreak in the Kingdom of Tonga and has been characterized as causing mild disease and having a low virus isolation rate (13). rDEN2Δ30 was originally developed as a DENV2 candidate vaccine virus; however, in preclinical studies it was not sufficiently attenuated compared with its parent virus (14). For that reason, rDEN2Δ30 was abandoned as a candidate vaccine, but since individuals vaccinated with rDEN2Δ30 demonstrated consistently detectable low-level viremia, it was suggested that this isolate might be suitable for use as a DENV2 challenge virus (15). Administration of rDEN2Δ30 to

TABLE 1 Homology of rDEN2Δ30 to other DENV sequences

Sequence	Homology of rDEN2Δ30 sequence to PL046 and DENV consensus sequences				Sequence of conserved and mismatched rDEN2Δ30 9- and 10-mer peptides compared to DENV consensus sequences ^a			Sequence of conserved and mismatched rDEN2Δ30 15-mer peptides compared to consensus sequences of four DENV serotypes ^b		
	Total no. of residues	No. of mismatched residues	No. of matched residues	% sequence identity	Total no. of peptides	No. of mismatched peptides	No. of matched peptides	Total no. of peptides	No. of mismatched peptides	No. of matched peptides
DENV1	3,393	936	2,457	72.41	6,765	3,756	3,009	3,377	1,767	1,610
DENV2 consensus	3,391	78	3,313	97.70	6,765	67	6,698	3,377	14	3,363
DENV3 consensus	3,393	946	2,445	72.06	6,765	3,860	2,905	3,377	1,782	1,595
DENV4 consensus	3,393	1,034	2,359	69.53	6,765	4,103	2,662	3,377	1,928	1,449
PL046	3,391	86	3,305	97.46						

^aIdentity, ≥80%.^bIdentity, ≥85%.

healthy volunteers was associated with detectable transient viremia in 100% of subjects, rash in 80% of subjects, and neutropenia in 40% of the individuals (15). Accordingly, rDEN2Δ30 has since been utilized as a challenge virus in a model of the protection conferred by the TV003 vaccine, which was found to confer complete protection from rDEN2Δ30 challenge (6).

Previous data addressed the suitability of the use of rDEN2Δ30 infection as a model of DENV2 infection predominantly on the basis of clinical parameters and the induction of serological responses. Since T cell responses are also potential correlates of protection in humans (12, 16), we sought to characterize the CD8⁺ and CD4⁺ T cell responses elicited in volunteers who were challenged with rDEN2Δ30 and compare the magnitude and specificity of these responses to those observed in the context of natural infection and in subjects from areas where DENV is hyperendemic.

RESULTS

Conservation of potential T cell epitopes in rDEN2Δ30 within DENV2. We compared the rDEN2Δ30 sequence to other DENV2 sequences. The rDEN2Δ30 amino acid sequence is 97.7% homologous to a DENV2 consensus sequence established by aligning the DENV2 sequences available in GenBank as previously described (16) and 97.5% homologous to an attenuated DENV2 sequence PL046 previously used in a murine model of DENV infection (7). In contrast, the homology between the rDEN2Δ30 sequence and the DENV1, DENV3, or DENV4 consensus sequence was, as expected, still appreciable but much lower (72.41%, 72.06%, and 69.53%, respectively; Table 1).

DENV epitopes with more than 2 substitutions (or 80% homology) minimally cross-react at the level of T cell responses (12). Accordingly, we generated all possible 9-, 10-, and 15-mer peptides from the rDEN2Δ30 proteome and compared their sequences to the DENV2 consensus sequence, allowing up to two mismatches for each peptide (which corresponds to >80% and >85% of identity for HLA class I and class II peptides, respectively). Out of the 6,765 total 9- and 10-mers, 6,698 were identical or ≥80% conserved (Table 1). Similarly, only 14 of the 3,377 15-mers were not homologous at the specified identity level (Table 1). As expected, analysis of the DENV1, DENV3, and DENV4 sequences revealed much lower numbers of peptides homologous at the specified identity levels (approximately half). In conclusion, the sequences of the majority of the short peptides encoded by the rDEN2Δ30 sequence are identical or highly homologous to the DENV2 consensus sequence, and thus, this isolate appears to be representative of known DENV2 isolates.

rDEN2Δ30 induces CD8 responses comparable to those seen in natural infection. To assess class I responses, peripheral blood mononuclear cells (PBMCs) from donors infected with rDEN2Δ30 were screened with peptide pools each consisting of 10 predicted class I binders. Pools associated with positive gamma interferon (IFN-γ) responses in an enzyme-linked immunosorbent spot (ELISPOT) assay were deconvoluted to identify the individual epitopes. T cell reactivity was detected in 7 of the 9

TABLE 2 HLA-A, -B, and -DRB1 types of recipients of the rDEN2Δ30 challenge strain analyzed in this study^a

LJI identifier	HLA type					
	HLA-A	HLA-A	HLA-B	HLA-B	HLA-DRB1	HLA-DRB1
GW0063	<u>A*01:01</u>	<u>A*23:01</u>	<u>B*07:02</u>	<u>B*58:01</u>	<u>DRB1*13:01</u>	<u>DRB1*13:04</u>
GW0064	<u>A*02:01</u>	<u>A*31:01</u>	<u>B*15:01</u>	<u>B*40:01</u>	<i>DRB1*04:04</i>	<i>DRB1*13:01</i>
GW0065	<u>A*02:60</u>	<u>A*03:01</u>	<u>B*35:01</u>	<u>B*42:01</u>	<u>DRB1*12:01</u>	<u>DRB1*15:03</u>
GW0066	<u>A*23:01</u>	<u>A*23:01</u>	<u>B*15:10</u>	<u>B*82:01</u>	<u>DRB1*11:01</u>	<u>DRB1*11:04</u>
GW0067	<u>A*02:02</u>	<u>A*74:01</u>	<u>B*15:03</u>	<u>B*15:16</u>	<u>DRB1*03:01</u>	<u>DRB1*03:02</u>
GW0068	<u>A*02:01</u>	<u>A*24:02</u>	<u>B*27:02</u>	<u>B*45:01</u>	<u>DRB1*01:02</u>	<u>DRB1*16:02</u>
GW0069	<u>A*02:01</u>	<u>A*29:02</u>	<u>B*44:03</u>	<u>B*45:01</u>	<u>DRB1*07:01</u>	<u>DRB1*13:02</u>
GW0070	<u>A*02:01</u>	<u>A*02:05</u>	<u>B*07:02</u>	<u>B*50:01</u>	<u>DRB1*07:01</u>	<u>DRB1*15:01</u>
GW0071	<u>A*68:01</u>	<u>A*74:01</u>	<u>B*15:03</u>	<u>B*58:01</u>	<u>DRB1*03:01</u>	<u>DRB1*03:02</u>
GW0073	<u>A*02:02</u>	<u>A*74:01</u>	<u>B*15:03</u>	<u>B*15:16</u>	<u>DRB1*07:01</u>	<u>DRB1*15:03</u>

^aHLA alleles tested in this study with a 2-digit or supertype match are underlined. HLA alleles not tested because the sets of predicted epitopes were not available are shown in regular type. HLA alleles not tested because cell numbers were not sufficient for testing are shown in italics.

(78%) individuals immunized with rDEN2Δ30. This is in line with the notion that the two vaccine recipients that did not respond (GW0066 and GW0067) expressed HLA alleles that have previously been associated with low frequencies of responses in natural infection (Table 2) (16).

For each HLA class I allele, Table 3 lists the number of tested donors expressing the indicated HLA molecules, the average number of epitopes detected in those donors, the average magnitude of these responses detected, and the sum total response of all positive responses (averaged over the number of donors tested to normalize for the different number of tested donors expressing the various HLA class I alleles). Considering the 13 HLA alleles studied, the response magnitudes were, on average, 302.1 spot-forming cells (SFC) per allele, with an average repertoire breadth of 1.5 epitopes per HLA per donor and an average magnitude of 106 IFN- γ -producing SFC per epitope.

Next, we compared the responses observed here in rDEN2Δ30-immunized volunteers with the responses observed when the same set of peptides was previously tested in the context of natural infection. Accordingly, in Table 3 we also show for each allele the average number of epitopes identified, the average magnitude of the responses, and the sum total response previously detected and reported in the context of natural infection (16). We observed that the responses to rDEN2Δ30 were associated with similar numbers of epitopes (1.5, on average, versus 1 for natural infection; $P = 0.9886$ by the Mann-Whitney t test) and a similar magnitude of response per epitope (106.4

TABLE 3 CD8 immune response per HLA allele in rDEN2Δ30 vaccinees and individuals with natural infection

HLA allele	Results for rDEN2Δ30 vaccinees				Results for individuals with natural infection			
	No. of donors tested	Avg no. of epitopes/donor	Avg response/epitope for positive donors (no. of SFC/10 ⁶ PBMCs)	Total avg response/tested donor (no. of SFC/10 ⁶ PBMCs)	No. of donors tested	Avg no. of epitopes/donor	Avg response/epitope for positive donors (no. of SFC/10 ⁶ PBMCs)	Total avg response/tested donor (no. of SFC/10 ⁶ PBMCs)
A*01:01	1	2.0	210.0	420.0	49	0.1	100.0	8.2
A*02:01	6	2.8	56.8	160.8	55	0.4	102.0	40.9
A*03:01	2	0.0	0.0	0.0	28	0.2	263.0	48.4
A*23:01	2	0.0	0.0	0.0	6	0.0	0.0	0.0
A*24:02	1	0.0	0.0	0.0	75	0.2	124.0	27.3
A*31:01	1	0.0	0.0	0.0	15	0.1	80.0	10.7
A*68:01	1	0.0	0.0	0.0	29	0.3	217.0	102.9
B*07:02	2	5.5	231.7	1,274.2	48	2.1	185.0	392.1
B*15:01	3	0.0	0.0	0.0	68	0.5	54.0	26.5
B*35:01	1	2.0	301.7	603.3	59	6.5	215.0	1,615.5
B*40:01	1	2.0	196.7	393.3	59	0.4	451.0	203.0
B*44:03	1	3.0	221.7	665.0	43	0.3	129.0	47.8
B*58:01	2	2.5	164.3	410.8	37	1.4	208.0	308.5
Avg	1.8	1.5	106.4	302.1	43.9	1.0	163.7	217.8




FIG 1 Protein locations of CD8 epitopes from individuals immunized with rDENV2Δ30 compared to those from individuals with natural infection (NI). The magnitude of the DENV2 response was analyzed by considering the overall protein composition (in percent). (A) Protein composition of the CD8 T cell response in rDENV2Δ30-immunized individuals; (B) protein composition of the CD8 T cell response in DENV2-infected donors in areas of hyperendemicity (16).

versus 163.7 SFC/10⁶ PBMC; $P = 0.2817$ by the Mann-Whitney t test) and the overall magnitudes of the responses (302.1 versus 217.8 SFC/10⁶ PBMC; $P > 0.9999$ by the Mann-Whitney t test).

Protein targets of CD8 responses are similar for rDENV2Δ30 and DENV natural infection. Next, we analyzed the specificity of the rDENV2Δ30 immune response at the antigen level. To this end, we calculated the relative fraction of the total magnitude (number of SFCs per 10⁶ PBMCs) of the total response directed against each of the 10 DENV proteins, namely, the three structural proteins (the capsid [C], membrane [M], and envelope [E] proteins) and the seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). As shown in Fig. 1A, the CD8 T cell response against rDENV2Δ30 was broad and targeted 9 out of the 10 proteins. The majority of the epitopes were derived from NS proteins and accounted for 88% of the total IFN- γ response observed. Among the seven nonstructural proteins, NS3 and NS5 were the most dominantly targeted, accounting for 31% and 19% of the total IFN- γ response, respectively.

Next, these rDENV2Δ30-specific CD8 responses were compared to the response patterns of recognition following natural infection at the level of DENV2-specific epitopes as previously described (12). In accordance with the previous results, the overall pattern of recognition of CD8 responses to rDENV2Δ30 was remarkably similar to the CD8 response to natural infection, with NS3 and NS5 accounting for 31% and 19% of the total response, respectively (Fig. 1B). NS1 is the only protein for which we observed an increase in the response in individuals inoculated with rDENV2Δ30, in which the response was more than 10% of the total response, whereas the response in naturally infected individuals was 1% of the total response (Fig. 1B).

The rDENV2Δ30 strain-induced CD4 responses are lower than those seen in natural infection. Purified CD4 cells from the rDENV2Δ30-infected donors were also screened for reactivity against HLA class II peptides, as described in Materials and Methods, using an *in vitro* restimulation step (17). Pools associated with positive responses in the IFN- γ ELISPOT assay were deconvoluted to identify the individual epitopes. T cell reactivity was detected in 8 of the 9 (89%) rDENV2Δ30 recipients.

For each HLA allele, Table 4 lists the number of donors expressing the HLA-DRB1 allele that were tested, the average number of epitopes detected, the average response magnitude, and the sum total response of all positive responses restricted by that allele normalized for the number of donors expressing the specific HLA-DRB1 allele. Considering the seven HLA alleles studied, response magnitudes were, on average, 539.2 SFC/allele, with an average repertoire breadth of 2 epitopes per HLA and an average magnitude of 1,541.1 SFC/epitope.

Since the same sets of peptides tested in the present study were also previously tested in the context of natural infection, this allowed a comparison of the magnitude of the responses observed for the various peptide sets in HLA-matched donors in the context of natural infection. Accordingly, we observed that the responses to rDENV2Δ30 were associated with lower numbers of epitopes (2, on average, versus 8 for natural

TABLE 4 CD4 immune response per HLA allele in rDEN2Δ30 vaccinees and individuals with natural infection

HLA allele	Results for rDEN2Δ30 vaccinees				Results for individuals with natural infection			
	No. of donors tested	Average no. of epitopes/donor	Avg response/epitope for positive donors (no. of SFC/10 ⁶ PBMCs)	Total avg response/tested donor (no. of SFC/10 ⁶ PBMCs)	No. of donors tested	Avg no. of epitopes/donor	Avg response/epitope for positive donors (no. of SFC/10 ⁶ PBMCs)	Total avg response/tested donor (no. of SFC/10 ⁶ PBMCs)
DRB1*01:01	1	2.0	556.7	1,113.3	10	7.0	607.5	5,447.0
DRB1*03:01	2	2.0	714.4	1,470.0	10	3.0	656.7	1,858.0
DRB1*07:01	4	5.0	756.5	4,317.8	9	10.0	1,042.8	11,159.0
DRB1*11:01	1	0.0	0.0	0.0	8	2.0	743.9	1,421.0
DRB1*12:01	1	2.0	626.7	1,253.3	11	19.0	1,222.4	24,759.0
DRB1*13:01	1	2.0	530.0	1,060.0	18	10.0	989.6	11,732.0
DRB1*15:01	3	2.7	590.0	1,573.3	12	8.0	1,064.4	11,476.0
Avg	2	2.0	539.2	1,541.1	11	8.0	903.9	9,693.1


infection; $P < 0.0087$ by the Mann-Whitney test) and a lower magnitude of response per epitope (539.2 versus 903.9 SFC/10⁶ PBMC; $P < 0.0175$ by the Mann-Whitney test) and lower overall magnitudes of responses (1,541.1 versus 9,693.1 $P < 0.007$ by the Mann-Whitney test) (Table 4).

Overlap in protein targets of CD4 responses recognized in rDEN2Δ30 and natural infection. Next, we investigated to what extent CD4 responses associated with rDEN2Δ30 infection would mimic immunity resulting from naturally occurring DENV infections. As shown in Fig. 2A, the immune response against rDEN2Δ30 was also broad, with 9 out of 10 proteins being recognized. The majority of the epitopes were derived from NS3, NS2A, and C, and these accounted for 24%, 20%, and 16% of the total IFN- γ response observed, respectively.

Next, these rDEN2Δ30-specific responses were compared to the patterns of recognition observed following natural infection at the level of DENV2-specific epitopes, as previously described (12) and shown here in Fig. 2B for reference purposes. While all proteins were recognized in both cases, certain differences were noted. The NS3 antigen was recognized at similar levels in rDEN2Δ30-immunized individuals and individuals with natural infection, while NS2A was less dominantly recognized in individuals with natural infection. Further, the responses generated during primary natural infection showed that the C protein was recognized 2-fold more prominently after natural infection than after rDEN2Δ30 immunization (16% for rDEN2Δ30 immunization versus 39% for natural infection).

rDEN2Δ30 induces stronger CD8 responses than other, more attenuated DENV isolates. The data presented above demonstrate that the rDEN2Δ30 isolate induces CD8 responses similar in magnitude to those induced by natural infection. We previously reported an analysis of the CD8 responses induced by immunization with monovalent components of the tetravalent DENV live attenuated vaccine (DLAV)

A rDEN2Δ30 CD4 T cell response



B NI DENV2 CD4 T cell response




FIG 2 Protein locations of CD4 epitopes from individuals immunized with rDEN2d30 compared to those from individuals with natural infection. The magnitude of the DENV2 response was analyzed by considering the overall protein composition (in percent). (A) Protein composition of the CD4 T cell response in rDEN2Δ30-immunized individuals; (B) protein composition of the CD4 T cell response in DENV2-infected donors in areas of hyperendemicity (17).




FIG 3 CD8 immune response to rDEN2Δ30 compared to that to attenuated DENV vaccine strains. (A) Number of CD8-specific epitopes per donor in response to rDEN2Δ30 and the magnitude of the response in terms of the average number of SFC per donor. (B) Percentage of donors responding to rDEN2Δ30 with respect to that to other monovalent attenuated vaccine strains (12).

developed by the NIH (11). Here we compared the magnitude and breadth of the response and the response rates of CD8 T cells observed in the monovalent DLAV studies (12) with those of CD8 T cells observed in the current study. A similar analysis at the level of CD4 responses was not feasible since the CD4 immunogenicity of the attenuated viruses was evaluated only with the tetravalent formulation (8).

If the number of epitopes restricted by all HLA-A and HLA-B loci were taken into consideration, the breadth of the response induced by rDEN2Δ30 (mean, 7 epitopes per donor; range, 1 to 9 epitopes per donor) was comparable to that induced by other monovalent DLAVs (mean, 6 epitopes per vaccine; range, 3 to 8 epitopes per vaccine) (Fig. 3A). However, the magnitude of the response was higher for the rDEN2Δ30 isolate (average, 162 SFC/10⁶ PBMCs) than the other DLAVs (mean for the various DLAVs, 95 SFC/10⁶ PBMCs; range, 76 to 12,395 SFC/10⁶ PBMCs; $P = 0.017$ by the one-sample t test) (Fig. 3A). *Ex vivo* reactivity was detected in seven out of the nine infected volunteers (Fig. 3B) of the nine infected volunteers studied. This value was also higher than the values observed for the other DLAVs ($P = 0.0002$ by a one-sample t test).

Substantial overlap between epitope specificity of the CD4 and CD8 responses observed in rDEN2Δ30- and other DLAV-immunized individuals and those with natural infection. Based on the results presented above, we hypothesized that a substantial overlap might exist between the epitopes recognized in the context of rDEN2Δ30 experimental challenge/infection and those recognized in the context of DLAV vaccination and natural infection. A complete list of the CD8⁺ and 28 CD4⁺ T cell epitopes detected in the present study is provided in Table 5, which lists, for each epitope, the antigen of origin, the sequence, and the putative HLA restriction.

We next analyzed, for each of these epitopes, whether the same epitope reactivity was previously detected in the context of natural infection (16) or DLAV vaccination (12). We found that 100% of the CD8 epitopes (37 out of 37) and approximately 85% of the CD4 epitopes (26 out of 28) were previously observed in one or both of these systems.

Correlation of rDEN2Δ30 cellular responses with antibody titer and viremia. As shown in Table 6, antibody titers and viral loads were also determined for all vaccinees. The humoral response peak occurred on day 28 after vaccination, and no significant correlation between the antibody titer and the magnitude of the cellular immune response was observed (for CD4, $r = 0.3167$ and $P = 0.4101$; for CD8, $r = 0.4286$ and

TABLE 5 HLA class I and II epitopes detected in this study

HLA class and protein ^a	Sequence	HLA	Previously detected ^b
HLA class I			
C ₄₃₋₅₂	GPMKLVMAFI	HLA-B*0702	NI
E ₅₅₃₋₅₆₂	MSSGNLLFTG	HLA-B*5801	NI
E ₆₃₁₋₆₃₉	RLITVNPV	HLA-A*0201/0203	NI
E ₇₂₃₋₇₃₂	AIYGAAFSGV	HLA-A*0201/0203/0206	NI
E ₇₃₈₋₇₄₆	ILIGVIITW	HLA-B*5801	NI
E ₇₃₈₋₇₄₆	ILIGVVITW	HLA-B*5801	NI
NS1 ₉₆₈₋₉₇₆	RAVHADMGY	HLA-B*5801	NI
NS1 ₁₀₄₂₋₁₀₅₁	GPWHLGKLEL	HLA-B*0702	NI
NS2A ₁₁₄₆₋₁₁₅₅	FLEEMLRTRV	HLA-A*0201	NI
NS2A ₁₁₆₁₋₁₁₆₉	ILLVAVSFV	HLA-A*0201	NI
NS2A ₁₁₉₁₋₁₂₀₀	TMTDDIGMGV	HLA-A*0201	NI
NS2A ₁₂₃₀₋₁₂₃₉	MMATIGIALL	HLA-A*0201	NI
NS2A ₁₂₄₂₋₁₂₅₁	LSIPHDLMEF	HLA-A*0101	NI
NS2A ₁₂₅₁₋₁₂₅₉	LIDGISLGL	HLA-A*0101	NI
NS2A ₁₂₇₁₋₁₂₇₉	YQLAVTIMA	HLA-A*0201/0206	NI
NS2B ₁₄₆₄₋₁₄₇₃	TAAAWYLWEV	HLA-A*0201/0206/6802	NI
NS3 ₁₈₈₉₋₁₈₉₇	SEMGANFKA	HLA-B*4403	NI
NS3 ₁₉₀₂₋₁₉₁₀	DPRRCLKPV	HLA-B*0702	NI
NS3 ₁₉₇₈₋₁₉₈₇	TPEGIIPALF	HLA-B*0702/3501/5301	NI
NS3 ₁₉₇₈₋₁₉₈₇	TPEGIIPALF	HLA-B*3501	NI
NS3 ₂₀₇₀₋₂₀₇₈	RPRWLDART	HLA-B*0702	NI
NS4A ₂₂₀₇₋₂₂₁₆	LEFFLMVLLI	HLA-B*4403	NI
NS4B ₂₂₃₂₋₂₂₄₁	YVVIAILTVV	HLA-A*0201/6802	NI
NS4B ₂₂₈₀₋₂₂₈₈	RPASAWTLY	HLA-B*0702	NI
NS4B ₂₂₈₆₋₂₂₉₅	TLYAVATTFV	HLA-A*0201	NI
NS4B ₂₃₂₂₋₂₃₃₁	LMGLGKGWPL	HLA-A*0201	NI
NS4B ₂₃₅₉₋₂₃₆₇	LLLVAHYAI	HLA-A*0201	NI
NS4B ₂₄₁₉₋₂₄₂₈	MLLILCVTQV	HLA-A*0201	NI
NS4B ₂₄₂₀₋₂₄₂₈	LLILCVTQV	HLA-A*0201	NI
NS5 ₂₆₇₇₋₂₆₈₅	VLNPYMPVS	HLA-A*0201	NI
NS5 ₂₆₀₉₋₂₆₁₈	IPMSTYGNL	HLA-B*0702	NI
NS5 ₂₆₀₉₋₂₆₁₈	IPMATYGNL	HLA-B*0702	NI
NS5 ₂₉₁₉₋₂₉₂₈	EAVEDGRFWE	HLA-B*5801	NI
NS5 ₂₉₂₁₋₂₉₂₉	VEDEFWKL	HLA-B*4001	NI
NS5 ₃₀₅₈₋₃₀₆₆	KLAEAIFKL	HLA-A*0201	NI
NS5 ₃₁₁₀₋₃₁₁₈	MEVQLVRQM	HLA-B*4001	NI
NS5 ₃₂₀₀₋₃₂₀₉	QQVPFCSHHF	HLA-B*4403	NI
HLA class II			
C ₄₅₋₅₉	LRLFMALVAFLRFLT	HLA-DRB1*1501	NI
C ₇₀₋₈₄	WGTIKSKAINVLRG	HLA-DRB1*0701	NI/DLAV
E ₅₁₂₋₅₂₆	WIQKELVTFKNPHA	HLA-DRB1*1501	NI/DLAV
E ₅₁₃₋₅₂₇	NRKELLVTFKNAHAK	HLA-DRB1*1501	NI/DLAV
E ₅₄₇₋₅₆₁	GATEIQMSSGNLLFT	HLA-DRB1*0301	NI
M ₂₄₂₋₂₅₆	ILRHGPTLMAAAILA	HLA-DRB1*0701/HLA-DRB1*1501	NI/DLAV
M ₂₄₂₋₂₅₆	ILRHGPTLMAAAILA	HLA-DRB1*1501	NI
M ₂₆₄₋₂₇₈	FQRLIFILLTAVAP	HLA-DRB1*0701	NI/DLAV
NS1 ₈₆₀₋₈₇₄	VKLTIMTGDIKGIMQ	HLA-DRB1*0301	NI
NS1 ₈₆₁₋₈₇₅	KLTIMTGDIKGIMQA	HLA-DRB1*0301	NI/DLAV
NS2A ₁₁₉₇₋₁₂₁₁	GMGVTYLALLAAYKV	HLA-DRB1*0101	NI
NS2A ₁₁₉₉₋₁₂₁₃	GVTYLLALLAFAKVRP	HLA-DRB1*0101	NI
NS2A ₁₂₃₁₋₁₂₄₅	LLTIGLSLVAVELP	HLA-DRB1*0701	NI/DLAV
NS2A ₁₂₅₇₋₁₂₇₁	LGMMVLKIVRNMEKY	HLA-DRB1*1202	NI
NS2A ₁₂₈₄₋₁₂₉₈	NTIFLTVAWRTATL	HLA-DRB1*0701	NI/DLAV
NS2B ₁₃₅₅₋₁₃₆₉	IMAVGIVSILLSLL	HLA-DRB1*0701	NI/DLAV
NS2B ₁₃₅₆₋₁₃₇₀	MAVGMSILASLLK	HLA-DRB1*0701	NI/DLAV
NS3 ₁₅₂₁₋₁₅₃₅	GTFHTMWHVTRGAVL	HLA-DRB1*0701	NI/DLAV
NS3 ₁₅₂₃₋₁₅₃₇	FHTMWHVTRGAVLTY	HLA-DRB1*0701	NI/DLAV
NS3 ₁₅₂₃₋₁₅₃₇	FHTMWHVTRGAVLMH	HLA-DRB1*0701	NI/DLAV
NS3 ₁₅₃₄₋₁₅₄₈	VLMHKGKRIEPSWAD	HLA-DRB1*1301	NI
NS3 ₁₆₂₀₋₁₆₃₄	KGKVVGLYGNGVVTR	HLA-DRB1*1501	NI
NS3 ₁₆₂₁₋₁₆₃₅	GKIVGLYGNGVTTTS	HLA-DRB1*1501	NI
NS3 ₁₈₅₀₋₁₈₆₄	TNCLRKNGKRVIQLS	HLA-DRB1*1301	NI
NS4A ₂₁₇₉₋₂₁₉₃	LGMCCIIATASILLWY	HLA-DRB1*0701	DLAV
NS4B ₂₄₁₇₋₂₄₃₁	QIMLLILCTSQILLM	HLA-DRB1*0701	NI/DLAV
NS4B ₂₄₂₃₋₂₄₃₇	LCAVQLLLMRTSWAL	HLA-DRB1*1202	NI/DLAV
NS5 ₂₈₇₄₋₂₈₈₈	RWLWGLFSRNKKPRI	HLA-DRB1*1501	NI/DLAV

^aSubscript numbers indicate the amino acid positions of the indicated protein.^bNI, natural infection; DLAV, DENV live-attenuated vaccine.

TABLE 6 Antibody titers and levels of viremia in the rDEN2Δ30 vaccinees analyzed in this study

LJI identifier	Antibody (DENV2) titer on day:				Level of viremia (log ₁₀ no. of PFU/ml) on day:							
	0	28	56	180	0	2	4	6	8	10	12	14
GW0063	0	158	133	46	0	0	1.2	2.5	1.6	1.5	0.5	0
GW0064	0	1,185	109	29	0	0	1.7	2.7	2.3	0.5	0	0
GW0065	0	1,071	519	38	0	0	NA ^a	2.8	2.3	0	0	0
GW0066	0	459	147	38	0	0	0	2	2.4	1.5	0.5	0
GW0067	0	764	244	72	0	0	0.5	1.8	2.4	2.6	1.3	0
GW0068	0	678	469	53	0	0	1.5	1.5	1	0	0	0
GW0069	0	1,966	820	NA	0	0	1	2.6	2	0.5	0	0
GW0070	0	1,435	272	NA	0	0	1.5	2.8	2.1	0	NA	0
GW0071	0	107.3	113.9	NA	0	0	0	0	1	1.5	0.5	0.5
GW0072	0	120	169.8	NA	0	0	0.5	1.7	1.3	0.5	0.5	0
GW0073	0	120.4	53.6	NA	0	0	0	2.2	2.1	1.5	0.5	0

^aNA, not available.

$P = 0.3536$). The viral load peak was observed at day 6 in 8 out of 10 donors, while only 2 donors showed viral load peak after 8 days of inoculation. A significant negative correlation between the viral load and the magnitude of the CD8 response was observed ($r = -0.8310$, $P = 0.0071$), while no significant correlation was observed when CD4 responses were considered ($r = -0.3504$, $P = 0.3536$).

DISCUSSION

The rDEN2Δ30 isolate cross-reacts with other DENV2 isolates at the serological level (12, 14, 16). While serological cross-reactivity can be dependent on the conservation of conformational determinants on viral surface proteins, cross-reactivity at the level of CD8 and CD4 immunity is dependent on the homology of 9- or 10- and 15-residue peptides, respectively. Here we show that the majority of the peptides that were of 9 to 15 amino acid residues and that thus were potentially recognized by CD8 and CD4 T cells are conserved between rDEN2Δ30 and other DENV2 isolates, thus providing support for the notion that rDEN2Δ30 might induce T cell responses with specificities similar to those induced by DENV2 in the context of natural infection.

In terms of CD8/class I responses, we observed that the overall magnitude and breadth of the responses were very comparable to those observed and previously reported in the context of natural infection with PBMC donations derived from the area of Sri Lanka where dengue is hyperendemic (16). A similar pattern of immunodominance was observed for most of the NS proteins in rDEN2Δ30 vaccinees and those with natural infection, suggesting similar patterns of immune recognition of rDEN2Δ30 and DENV2. In particular, NS3 and NS5 are dominantly recognized in both contexts. The main differences in terms of response were observed in the response to the pre-membrane (prM) and NS1 proteins. It is possible that reduced viral replication due to the attenuation of rDEN2Δ30 leads to small differences in the protein recognition pattern. Overall, these data suggest that rDEN2Δ30 infection mimics wild-type DENV2 infection in terms of the immunodominance of MHC class I responses.

In contrast to the similar immunogenicity observed in the case of class I, the class II-restricted responses to rDEN2Δ30 infection were relatively less vigorous than those to natural DENV infection. Furthermore, the relative immunodominance observed in the case of rDEN2Δ30 was, in the case of class I-restricted responses, essentially superimposable with the pattern observed in the case of natural infection. Interestingly, a much less stringent correlation was observed in the case of the class II response. Here the main difference was that the C antigen, which is dominant in natural DENV infection, was still recognized in the context of rDEN2Δ30-induced responses but in a much less dominant manner, while, on the contrary, a stronger response against the NS1 protein was observed in rDEN2Δ30 infection. These observations may suggest that rDEN2Δ30 and the Tonga/74 wild-type strain in general have reduced rates of propagation (~100 PFU/ml) (3, 9, 18) compared to those of other wild-type DENV strains (106 to 109

PFU/ml) (19). If this is true, fewer virions containing the viral structural proteins would be released from infected cells and available for the exogenous pathway of antigen processing and presentation, which is most prominently involved in the generation of class II-restricted peptides. This would also reduce structural protein availability and recognition by the immune system, increasing the responses against the nonstructural proteins. In addition, this may also explain why the Tonga/74 strain was described to cause more mild illness (13).

We have previously studied the CD8 T cell response elicited by each of the monovalent DLAVs currently included in the TV003 vaccine (6). A comparison of the T cell responses elicited by each of the monovalent vaccines with vaccine-specific peptides from their corresponding serotypes demonstrated that the magnitude and the breadth of responses elicited by rDEN2Δ30 were higher. The higher immunogenicity of rDEN2Δ30 is consistent with the lower degree of attenuation (2.2 log₁₀ focus-forming units/ml for monovalent DLAVs versus ~0.5 log₁₀ focus-forming units/ml for rDEN2Δ30) (5, 14, 20) and with the significant negative correlation with the viral load observed in the case of CD8 responses, possibly suggesting that more viral replication results in at least moderately higher levels of immunogenicity. This effect has been reported in the context of other viral systems. A similar comparison of the various DLAVs and rDEN2Δ30 at the level of CD4 responses was not feasible since the CD4 immunogenicity of the attenuated viruses was evaluated only with the tetravalent formulation (8). Since no clinical evaluation of monovalent DLAVs is currently ongoing, samples for study were no longer available for our analysis.

To use the rDEN2Δ30 virus isolate as a DENV2 challenge agent, in the context of vaccination with other DLAVs, the epitopes recognized following experimental challenge/infection with rDEN2Δ30 must largely overlap those recognized in the context of DLAV vaccination and natural infection. The results obtained in this study demonstrate that this is indeed the case, providing an additional piece of evidence supporting the feasibility of using rDEN2Δ30 in a human DENV2 challenge model.

MATERIALS AND METHODS

Sequence conservation analysis. Full-length polyprotein sequences of each DENV serotype were retrieved from the NCBI Protein database as described previously (16). To eliminate geographical bias, the number of isolates from any one country was limited to 10. Sequences were considered unique if they varied by at least 1 amino acid from all other sequences. A total of 162 DENV1, 171 DENV2, 169 DENV3, and 53 DENV4 sequences were retrieved from the NCBI Protein database and utilized to evaluate the variability of the sequence of the rDEN2Δ30 strain compared with the sequences of the respective serotypes. All the sequences were aligned using MAFFT software online (v.7) (21), and consensus sequences were generated using BioEdit software (v.7.0) (22). Each consensus sequence was separately aligned to the rDEN2Δ30 sequence and analyzed for the number of matches and mismatches.

Human subjects. Volunteers previously infected with rDEN2Δ30 (ClinicalTrials.gov registration no. NCT01931176) were recalled to donate blood for this study (6). Full-blood units from 10 volunteers were collected 4 to 7 months after inoculation at the Johns Hopkins University Bloomberg School of Public Health (JHSPH) in Baltimore, MD, after informed consent was granted by the volunteers under a JHSPH Institutional Review Board (IRB)-approved protocol (IRB no. 00006691). PBMCs were purified, frozen, and shipped to the La Jolla Institute (LJI) for further analysis. Antibody titers and levels of viremia after vaccination were determined as previously described (14).

HLA typing. HLA typing for class II DRB1 was performed by an ASHI-accredited laboratory at Murdoch University (Western Australia, Australia) using locus-specific PCR amplification of genomic DNA. Patient-specific barcoded primers were used for amplification. The amplified products were quantitated and pooled by subject, and products from up to 48 subjects were pooled. An unindexed library (454 8-lane runs) or an indexed library (8 indexed MiSeq runs) was then quantitated using kappa universal quantitative PCR library quantification kits. Sequencing was performed using either a Roche 454 FLX+ sequencer with titanium chemistry or an Illumina MiSeq sequencer using 2 × 300 paired-end chemistry. Reads were quality filtered and passed through a proprietary allele-calling algorithm and analysis pipeline using the latest international ImMunoGeneTics project (IMGT) HLA allele database as a reference. Table 2 lists the HLA types of all donors used in this study.

HLA binding predictions. Major histocompatibility complex class I binding predictions and peptide selections were conducted using the Immune Epitope Database (IEDB) analysis resource (www.iedb.org) (23) as previously described (16, 24). The 9-mer and 10-mer peptides selected for synthesis were within the top 1% of the predicted binders for HLA class I A and B alleles frequently expressed in the study population. On average, 300 peptides (range, 275 to 332 peptides) were tested for each HLA class I allele. These peptide sets were subdivided into pools of 10 individual peptides and were previously utilized to characterize CD8 responses in the areas of Colombo, Sri Lanka, and Managua, Nicaragua, where dengue

is hyperendemic and in the context of vaccination with the tetravalent DENV live attenuated vaccine (TDLAV) (12, 16, 25). These peptide sets were previously utilized to characterize the CD4 responses in the areas of Colombo, Sri Lanka, and Managua, Nicaragua, where dengue is hyperendemic and in the context of vaccination with TDLAV (8, 12, 16).

To analyze DENV-specific HLA-restricted CD4 responses, we utilized sets of DENV peptides predicted to bind HLA-DRB1* allelic variants expressed in the donor population as previously described (8, 17). These sets of peptides included 15-mer HLA class II allele-restricted peptides (average, 130 peptides; range, 108 to 172 peptides) subdivided into pools of 20 individual peptides previously utilized to characterize CD4 responses in the area of Colombo, Sri Lanka, where dengue is hyperendemic and in the context of vaccination with TDLAV (8, 17).

Epitope predictions were performed using the consensus prediction methods publicly available through the IEDB analysis resource (www.iedb.org) (23, 26, 27). For each allele, we synthesized peptides predicted to bind at the 2% consensus threshold, after removing redundant peptides overlapping by 8 residues or more. This roughly corresponds to the top 10% of 15-mers overlapping by 10 residues (Mimotopes, Victoria, Australia).

In vitro expansion of DENV-specific T cells to study CD4 responses. PBMCs were thawed, and CD4⁺ T cells were isolated by magnetic bead negative selection and cultured separately in RPMI 1640 (Omega Scientific) supplemented with 5% human serum (Cellgro) at a density of 2×10^6 cells per ml in 24-well plates (BD Biosciences). Cells were cocultured with autologous antigen-presenting cells at a density of 1×10^6 cells/ml and stimulated with DENV-specific pools (average, 20 peptides per pool). Cells were kept at 37°C in 5% CO₂, and additional interleukin-2 (10 U/ml; eBioscience) was added 4, 7, and 11 days after the initial antigenic stimulation. On day 14, cells were harvested and screened for reactivity against individual DENV-specific peptides.

ELISPOT assays. PBMCs from immunized donors (2×10^5 cells/well) were incubated with 2 μg/ml of HLA-matched peptides in plates coated with the anti-human IFN-γ antibody 1-D1K (5 μg/ml; Mabtech) at 37°C for 20 to 24 h. The plates were then developed as previously described (16).

Strategy for assessment of CD8 and CD4 T cell responses. To assess the responses elicited by rDEN2Δ30, we used an approach previously utilized to characterize the responses to DLAV candidates (12) and to characterize the responses induced by natural infection in the area of Sri Lanka where dengue is endemic (16). This experimental design was chosen to enable comparison of the responses elicited by rDEN2Δ30 to those induced by DLAV or natural infection. This strategy is based on the testing of sets of peptides predicted to bind specific HLA alleles for recognition by PBMCs from HLA-matched donors.

Here, we utilized the same sets of peptides previously utilized in the DLAV and natural infection studies (8, 16, 17) and supplemented these sets of peptides with any additional predicted peptides uniquely found in the nucleic acid sequence of rDEN2Δ30. Full-blood units were collected from 10 rDEN2Δ30-infected volunteers 4 to 7 months following inoculation at JHSPH in Baltimore, MD. PBMCs were purified, frozen, and shipped to LJI for further analysis. PBMCs were tested with sets of peptides predicted to bind the HLA alleles expressed in the particular donor.

In the case of two donors, limited cell numbers were available, and accordingly, only predicted class I (donor GW0064) or class II (donor GW0073) epitopes were tested. Sets of predicted binders were available for 30 out of 36 instances in which a given HLA-A/B allele was expressed in the nine donors analyzed. Likewise, sets of predicted binders were available for 12 out of 18 instances in which a given HLA-DRB1 allele was expressed in the nine donors analyzed (Table 2).

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health contract no. HHSN272200900042C and HHSN27220140045C (to A.S.), by BMGF grant OPP1104710 (to A.P.D.), and in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH.

REFERENCES

1. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckennooghe A, CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet* 384:1358–1365. [https://doi.org/10.1016/S0140-6736\(14\)61060-6](https://doi.org/10.1016/S0140-6736(14)61060-6).
2. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, CYD15 Study Group. 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. *N Engl J Med* 372:113–123. <https://doi.org/10.1056/NEJMoa1411037>.
3. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckennooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet* 380:1559–1567. [https://doi.org/10.1016/S0140-6736\(12\)61428-7](https://doi.org/10.1016/S0140-6736(12)61428-7).
4. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckennooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, CYD-TDV Dengue Working Group. 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. *N Engl J Med* 373:1195–1206. <https://doi.org/10.1056/NEJMoa1506223>.
5. Srikiatkachorn A, Yoon IK. 2016. Immune correlates for dengue vaccine development. *Expert Rev Vaccines* 15:455–465. <https://doi.org/10.1586/14760584.2016.1116949>.
6. Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA,

- Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP. 2016. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. *Sci Transl Med* 8:330ra336. <https://doi.org/10.1126/scitranslmed.aaf1517>.
7. Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, Kolla RV, De Silva AD, de Silva AM, Grey H, Peters B, Shresta S, Sette A. 2011. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. *J Immunol* 187:4268–4279. <https://doi.org/10.4049/jimmunol.1101970>.
 8. Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D. 14 December 2016. Human CD4⁺ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity. *J Virol*. <https://doi.org/10.1128/JVI.02147-16>.
 9. Osorio JE, Wallace D, Stinchcomb DT. 2016. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. *Expert Rev Vaccines* 15:497–508. <https://doi.org/10.1586/14760584.2016.1128328>.
 10. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naïve adults: a randomized, double-blind clinical trial. *J Infect Dis* 207:957–965. <https://doi.org/10.1093/infdis/jis936>.
 11. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. 2015. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naïve adults. *J Infect Dis* 212:702–710. <https://doi.org/10.1093/infdis/jiv082>.
 12. Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, de Silva AD, Lindow JC, Diehl SA, Whitehead S, Durbin A, Kirkpatrick B, Sette A. 2015. The human CD8⁺ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. *J Virol* 89:120–128. <https://doi.org/10.1128/JVI.02129-14>.
 13. Gubler DJ, Reed D, Rosen L, and Hitchcock JR, Jr. 1978. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. *Am J Trop Med Hyg* 27:581–589.
 14. Blaney JE, Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. 2004. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. *BMC Infect Dis* 4:39. <https://doi.org/10.1186/1471-2334-4-39>.
 15. Larsen CP, Whitehead SS, Durbin AP. 2015. Dengue human infection models to advance dengue vaccine development. *Vaccine* 33:7075–7082. <https://doi.org/10.1016/j.vaccine.2015.09.052>.
 16. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A. 2013. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8⁺ T cells. *Proc Natl Acad Sci U S A* 110:E2046–E2053. <https://doi.org/10.1073/pnas.1305227110>.
 17. Weiskopf D, Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, De Silva AD, Phillips E, Mallal S, Premawansa S, Premawansa G, Wijewickrama A, Peters B, Sette A. 2016. HLA DRB1 alleles are associated with different response magnitudes of dengue virus specific CD4⁺ T cell responses. *J Infect Dis* 214:1117–1124. <https://doi.org/10.1093/infdis/jiw309>.
 18. Ferguson NM, Cucunuba ZM, Dorigatti I, Nedjati-Gilani GL, Donnelly CA, Basanez MG, Nouvellet P, Lessler J. 2016. Epidemiology. Countering the Zika epidemic in Latin America. *Science* 353:353–354. <https://doi.org/10.1126/science.aag0219>.
 19. Vaughn DW, Green S, Kalayanaraj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. *J Infect Dis* 181:2–9. <https://doi.org/10.1086/315215>.
 20. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. 2011. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. *Vaccine* 29:7242–7250. <https://doi.org/10.1016/j.vaccine.2011.07.023>.
 21. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 30:772–780. <https://doi.org/10.1093/molbev/mst010>.
 22. Hall T. 2011. BioEdit: an important software for molecular biology. *GERF Bull Biosci* 2:60–61.
 23. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, Wheeler DK, Gabbard JL, Hix D, Sette A, Peters B. 2015. The Immune Epitope Database (IEDB) 3.0. *Nucleic Acids Res* 43:D405–D412. <https://doi.org/10.1093/nar/gku938>.
 24. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette A, Lund O, Bourne PE, Nielsen M, Peters B. 2012. Immune Epitope Database analysis resource. *Nucleic Acids Res* 40:W525–W530. <https://doi.org/10.1093/nar/gks438>.
 25. Weiskopf D, Cerpas C, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, Sanches FP, Silvera CG, Costa PR, Kallas EG, Gresh L, de Silva AD, Balmaseda A, Harris E, Sette A. 2015. Human CD8⁺ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. *J Infect Dis* 212:1743–1751. <https://doi.org/10.1093/infdis/jiv289>.
 26. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. *PLoS Comp Biol* 4:e1000048. <https://doi.org/10.1371/journal.pcbi.1000048>.
 27. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. 2010. Peptide binding predictions for HLA DR, DP and DQ molecules. *BMC Bioinformatics* 11:568. <https://doi.org/10.1186/1471-2105-11-568>.